Alimera Sciences Inc (NASDAQ:ALIM)’s stock price rose 6% during mid-day trading on Wednesday . The stock traded as high as $0.36 and last traded at $0.35, approximately 995,505 shares were traded during trading. An increase of 656% from the average daily volume of 131,688 shares. The stock had previously closed at $0.33.

Several brokerages recently issued reports on ALIM. HC Wainwright set a $2.00 price target on Alimera Sciences and gave the stock a “buy” rating in a report on Wednesday, September 4th. Craig Hallum began coverage on Alimera Sciences in a research report on Tuesday, May 28th. They issued a “buy” rating and a $3.00 price target for the company. Zacks Investment Research upgraded Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, ValuEngine raised shares of Alimera Sciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $2.00.

The firm’s fifty day moving average is $0.53 and its two-hundred day moving average is $0.86.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.03). The business had revenue of $10.86 million for the quarter, compared to analyst estimates of $12.97 million. Analysts forecast that Alimera Sciences Inc will post -0.16 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Knott David M grew its holdings in shares of Alimera Sciences by 3.9% in the first quarter. Knott David M now owns 402,901 shares of the biopharmaceutical company’s stock valued at $427,000 after acquiring an additional 15,000 shares in the last quarter. B. Riley Wealth Management Inc. lifted its holdings in Alimera Sciences by 36.7% during the first quarter. B. Riley Wealth Management Inc. now owns 139,302 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 37,396 shares during the period. Columbia Pacific Advisors LLC bought a new stake in Alimera Sciences during the first quarter worth $54,000. Tower Research Capital LLC TRC lifted its holdings in Alimera Sciences by 32,745.5% during the second quarter. Tower Research Capital LLC TRC now owns 54,852 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 54,685 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Alimera Sciences by 13.1% in the second quarter. Renaissance Technologies LLC now owns 1,128,404 shares of the biopharmaceutical company’s stock worth $1,004,000 after purchasing an additional 130,414 shares during the last quarter. Hedge funds and other institutional investors own 50.39% of the company’s stock.

Alimera Sciences Company Profile (NASDAQ:ALIM)

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Read More: How is a price target determined?

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.